News | Molecular Imaging | August 19, 2015

Molecular Breast Imaging Deemed Cost-Effective Secondary Breast Cancer Screening Technology

Mayo Clinic study finds four-fold increase in cancer detection rates for women with dense breast tissue at a 15 percent cost reduction

Mayo Clinic, molecular breast imaging, MBI, secondary screening, breast cancer, study, cost-effective

August 19, 2015 — A recent study by Mayo Clinic determined that adding molecular breast imaging (MBI) for women with dense breast tissue resulted in a lower cost per cancer detected than screening with mammography alone. The MBI technology known as LumaGEM, developed and commercialized by Gamma Medica Inc., is a cost-effective tool for detecting early-stage cancers in women who have dense fibroglandular breast tissue, which accounts for 45 percent of all women.

The study, published in the American Journal of Roentgenology (AJR) and entitled, "Diagnostic Workup and Costs of a Single Supplemental Molecular Breast Imaging Screen of Mammographically Dense Breasts," found MBI technologies led to more accurate diagnosis rates, and in combination with mammography, resulted in a cost savings of approximately 15 percent.

An additional publication of the Mayo Clinic study in AJR entitled, "Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts," concluded there was a four-fold increase in detection rates as compared with standard mammography when using LumaGEM as a secondary screening method. Unlike mammography, tomosynthesis and ultrasound – all of which are anatomical imaging tests – the LumaGEM system is a functional imaging modality that highlights the metabolic activity in the breast regardless of tissue density. This allows radiologists to clearly identify early stage cancers. MBI provides equivalent sensitivity, and improved specificity, when compared to MRI, but at roughly one-third of the cost.

About one in every eight women in the United States will develop breast cancer during their lifetime. Nearly one in two women have dense breast tissue, which masks early stages of cancer in traditional screening methods, often leading to missed opportunities for early intervention. Early detection through screening remains the most reliable method to manage the disease. However, for women with dense breast tissue standard mammography and 3-D tomosynthesis lack the clarity and accuracy to detect early stage cancers.

For more information: www.gammamedica.com

Related Content

Fujifilm Installing New DR Equipment for Three Large Healthcare Systems
News | Digital Radiography (DR) | September 22, 2017
Fujifilm Medical Systems U.S.A. Inc. recently closed new contracts to enhance diagnostic imaging capabilities for...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
DenseBreast-info.org Debuts  Spanish Language Video  About Dense Breasts
News | Breast Density | September 12, 2017
Breast cancer risks associated with breast density are the subject of a new Spanish language video launched recently by...
Asian Study Underlines Potential Value of Pressure-Guided Mammography
News | Mammography | September 11, 2017
Sigmascreening recently announced that a study of in total 15,898 in digital mammograms from 3,772 Asian women...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Breast imaging X-ray mammogram showing a breast tumor. Photo courtesy of Monthian Ritchan-Ad

Photo courtesy of Monthian Ritchan-Ad

Feature | Breast Density | September 08, 2017 | By Roy Prager, M.D.
While mammograms play a vital role in efforts to identify breast cancer, they can present some challenges in women with...
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Overlay Init